Novel treatments with small molecules in psoriatic arthritis

Current Rheumatology Reports

Volumn 16, Issue 9, 2014, Pages

  Hansen, Renata Baronaite ^a,c   Kavanaugh, Arthur ^b  

^a Mental Health Services CPH   (Denmark)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Apremilast; Janus kinase inhibitors; Psoriasis; Psoriatic arthritis

Indexed keywords

AE 941; APREMILAST; BARICITINIB; BMS 582949; DECERNOTINIB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ENZYME ACTIVATOR; FILGOTINIB; GLPG 0634; HEMOGLOBIN; INCB 039110; JANUS KINASE INHIBITOR; LESTAURTINIB; LIPOPROTEIN; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PLACEBO; SIRTUIN 1; SOTRASTAURIN; SRT 2104; TOFACITINIB; UNCLASSIFIED DRUG; VX 702; ANTIRHEUMATIC AGENT; JANUS KINASE; PHOSPHODIESTERASE INHIBITOR; THALIDOMIDE;

ARTICLE; CONCENTRATION RESPONSE; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERANCE; DRUG WITHDRAWAL; ESOPHAGUS CANDIDIASIS; FATIGUE; FUNCTIONAL STATUS; HEADACHE; HERPES ZOSTER; HUMAN; LEUKOPENIA; LIVER FUNCTION TEST; LYMPHOCYTOPENIA; MULTICENTER STUDY (TOPIC); NAUSEA; NEUTROPENIA; NON MELANOMA SKIN CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RHINOPHARYNGITIS; TREATMENT DURATION; TREATMENT FAILURE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VISUAL ANALOG SCALE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC;

ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; HUMANS; JANUS KINASES; PHOSPHODIESTERASE INHIBITORS; THALIDOMIDE;

EID: 84904217574     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-014-0443-6     Document Type: Article

References (39)

1. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68(9):1387-94.
2. Kavanaugh AF, Ritchlin CT. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol. 2006;33(7):1417-21. (Pubitemid 44025162)
3. Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71(1):4-12.
4. Ash Z, Gaujoux-Viala C, Gossec L, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2012;71(3):319-26.
5. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190-9.
6. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17- receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181-9.
7. Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2(52):52ra72.
8. Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168(2):412-21.
9. Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013;168(2):402-11.
10. Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum. 2011;63(4):939-48.
11. Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem. 2007;76:481-511.
12. • Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83(12):1583-90. A good article providing a thorough description of mechanism of action of PDE4 inhibitor apremilast.
13. Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today. 2005;10(22):1503-19. (Pubitemid 41527193)
14. Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159(4):842-55.
15. McCann FE, Palfreeman AC, Andrews M, et al. Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. Arthritis Res Ther. 2010;12(3):R107.
16. Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet. 2012;380(9843):738-46.
17. Papp KA, Kaufmann R, Thaci D, Hu C, Sutherland D, Rohane P. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dosecomparison study. J Eur Acad Dermatol Venereol. 2013;27(3):e376-83.
18. • Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2012;64(10):3156-67. Important article describing a phase II study showing efficacy of apremilast in joint symptoms in patients with PsA.
19. Strand V, Schett G, Hu C, et al. Patient-reported health-related quality of life with apremilast for psoriatic arthritis: a phase II, randomized, controlled study. J Rheumatol. 2013;40(7):1158-65.
20. •• Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73:1020-6. Important article describing a phase III study on apremilast in 504 patients with PsA. Apremilast demonstrated efficacy in improving skin and joint symptoms, as well as enthesitis and dactylitis.
21. Cutolo M, Myerson GE, Fleischmann RM, et al. Long-term (52-week) results of a Phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 2) [abstract]. Arthritis Rheum. 2013;65(Suppl):S346. This abstract describes efficacy of a apremilast in improving joint symptoms, the Health assessment questionnaire disability index, Medical Outcomes Survey Short form-36 Physical Functioning and skin at 52 weeks of treatment in a phase III study of 484 patients with PsA.
22. Edwards CJ, Blanco FJ, Crowley J, et al. Long-term (52-week) results of a Phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement (PALACE 3) [abstract]. Arthritis Rheum. 2013;65(Suppl):S132.
23. •• Gladman DD, Mease PJ, Kavanaugh A, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvements in enthesitis and dactylitis in patients with psoriatic arthritis: pooled results from three Phase 3, randomized, controlled trials [abstract]. Arthritis Rheum. 2013;65(Suppl):S347. This article provides a description of the efficacy of apremilast in improving dactylitis and enthesitis in PsA patients in three phase III studies.
24. • Mease PJ, Kavanaugh A, Gladman DD, et al. Long-term safety and tolerability of apremilast, an oral phospho- diesterase 4 inhibitor, in patients with psoriatic arthritis: pooled safety analysis of three Phase 3, randomized, controlled trials [abstract]. Arthritis Rheum. 2013;65(Suppl):S131. This article provides a describtion of adverse events of apremilast from three phase III studies.
25. Mease PJ, Kavanaugh A, Adebajo AO, et al. Laboratory abnormalities in patients with psoriatic arthritis receiving apremilast, an oral phosphodiesterase 4 inhibitor: pooled safety analysis of three Phase 3, randomized, controlled trials [abstract]. Arthritis Rheum. 2013;65(Suppl):S151.
26. • Kontzias A, Kotlyar A, Laurence A, Changelian P, O'Shea JJ. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol. 2012;12(4):464-70. This article describes the mechanism of action of JAK inhibitors.
27. Meyer SC, Levine RL. Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. Clin Cancer Res. 2014;20:2051-9.
28. • Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167(3):668-77. This study describes the efficacy of JAK inhibitor tofacitinib in improving skin symptoms in a phase II study in patients with psoriasis.
29. • Mamolo C, Harness J, Tan H, et al. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol. 2013.doi:10.1111/ jdv.12081. This article describes the efficacy of JAK inhibitor tofacitinib in improving patient-reported outcomes in phase II study in patients with psoriasis.
30. Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381(9865):451-60.
31. van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65(3):559-70.
32. Kremer J, Li ZG, Hall S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159(4):253-61.
33. • Gaujoux-Viala C, Nam J, Ramiro S, et al. Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014;73(3):510-5. A good review of adverse events of tofacitinib in RA patients.
34. Macfarlane LA, Todd DJ. Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis. Int J Rheum Dis. 2014;17(4):359-68.
35. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492-509.
36. Ports WC, Khan S, Lan S, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol. 2013;169(1):137-45.
37. Menter A, Papp K, Janes J, et al. A Phase 2b trial of baricitinib, an oral JAK inhibitor, in patients with moderate-to-severe psoriasis [abstract]. J Am Acad Dermatol. 2014;70(5):AB162.
38. Ryan C, Abramson A, Patel M, et al. Current investigational drugs in psoriasis. Expert Opin Investig Drugs. 2012;21(4):473-87.
39. Skvara H, Dawid M, Kleyn E, et al. The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. J Clin Invest. 2008;118(9):3151-9.